Discovery & development of selective M3 antagonists for clinical use.

@article{Alabaster1997DiscoveryD,
  title={Discovery & development of selective M3 antagonists for clinical use.},
  author={Valerie A. Alabaster},
  journal={Life sciences},
  year={1997},
  volume={60 13-14},
  pages={
          1053-60
        }
}
The treatment of airway obstructive disease may be improved by antimuscarinic agents which selectively block M1 and M3 receptors but do not inhibit prejunctional cholinergic autoreceptors which limit release of acetylcholine. Revatropate is a novel antimuscarinic agent which shows some 50-fold selectivity for M1 and M3 receptors in guinea pig trachea and rabbit vas deferens over the M2 subtype in atria. This selectivity profile was seen in vivo in anaesthetised guinea pigs and conscious dogs… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Pharmacological treatment of urinary incontinence.

  • Female pelvic medicine & reconstructive surgery
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND